Literature DB >> 22911446

Detailed mechanism of the autoxidation of N-hydroxyurea catalyzed by a superoxide dismutase mimic Mn(III) porphyrin: formation of the nitrosylated Mn(II) porphyrin as an intermediate.

József Kalmár1, Bernadett Biri, Gábor Lente, István Bányai, Ana Budimir, Mladen Biruš, Ines Batinić-Haberle, István Fábián.   

Abstract

The in vitro autoxidation of N-hydroxyurea (HU) is catalyzed by Mn(III)TTEG-2-PyP(5+), a synthetic water soluble Mn(III) porphyrin which is also a potent mimic of the enzyme superoxide dismutase. The detailed mechanism of the reaction is deduced from kinetic studies under basic conditions mostly based on data measured at pH = 11.7 but also including some pH-dependent observations in the pH range 9-13. The major intermediates were identified by UV-vis spectroscopy and electrospray ionization mass spectrometry. The reaction starts with a fast axial coordination of HU to the metal center of Mn(III)TTEG-2-PyP(5+), which is followed by a ligand-to-metal electron transfer to get Mn(II)TTEG-2-PyP(4+) and the free radical derived from HU (HU˙). Nitric oxide (NO) and nitroxyl (HNO) are minor intermediates. The major pathway for the formation of the most significant intermediate, the {MnNO} complex of Mn(II)TTEG-2-PyP(4+), is the reaction of Mn(II)TTEG-2-PyP(4+) with NO. We have confirmed that the autoxidation of the intermediates opens alternative reaction channels, and the process finally yields NO(2)(-) and the initial Mn(III)TTEG-2-PyP(5+). The photochemical release of NO from the {MnNO} intermediate was also studied. Kinetic simulations were performed to validate the deduced rate constants. The investigated reaction has medical implications: the accelerated production of NO and HNO from HU may be utilized for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22911446      PMCID: PMC3507375          DOI: 10.1039/c2dt31200j

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  49 in total

Review 1.  High-valent iron and manganese complexes of corrole and porphyrin in atom transfer and dioxygen evolving catalysis.

Authors:  Mahdi M Abu-Omar
Journal:  Dalton Trans       Date:  2011-01-31       Impact factor: 4.390

2.  Inherent pitfalls in the simplified evaluation of kinetic curves.

Authors:  Balázs Kormányos; Attila K Horváth; Gábor Peintler; István Nagypál
Journal:  J Phys Chem A       Date:  2007-08-02       Impact factor: 2.781

3.  NO dismutase activity of seven-coordinate manganese(II) pentaazamacrocyclic complexes.

Authors:  Milos R Filipović; Katharina Duerr; Milos Mojović; Vladica Simeunović; Robert Zimmermann; Vesna Niketić; Ivana Ivanović-Burmazović
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

4.  Effects of hydroxyurea and L-arginine on the production of nitric oxide metabolites in cultures of normal and sickle erythrocytes.

Authors:  Masoud Nahavandi; Fatemeh Tavakkoli; Richard M Millis; Melville Q Wyche; Muhammad J Habib; Nasrin Tavakoli
Journal:  Hematology       Date:  2006-08       Impact factor: 2.269

5.  Hydroxyurea and radiation therapy in advanced cervical cancer.

Authors:  M S Piver; J J Barlow; V Vongtama; J Webester
Journal:  Am J Obstet Gynecol       Date:  1974-12-01       Impact factor: 8.661

6.  Water exchange rates of water-soluble manganese(III) porphyrins of therapeutical potential.

Authors:  Ana Budimir; József Kalmár; István Fábián; Gábor Lente; István Bányai; Ines Batinić-Haberle; Mladen Birus
Journal:  Dalton Trans       Date:  2010-03-26       Impact factor: 4.390

7.  A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity.

Authors:  Zrinka Rajic; Artak Tovmasyan; Ivan Spasojevic; Huaxin Sheng; Miaomiao Lu; Alice M Li; Edith B Gralla; David S Warner; Ludmil Benov; Ines Batinic-Haberle
Journal:  Free Radic Biol Med       Date:  2012-02-13       Impact factor: 7.376

8.  A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy.

Authors:  K R Bridges; G D Barabino; C Brugnara; M R Cho; G W Christoph; G Dover; B M Ewenstein; D E Golan; C R Guttmann; J Hofrichter; R V Mulkern; B Zhang; W A Eaton
Journal:  Blood       Date:  1996-12-15       Impact factor: 22.113

9.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.

Authors:  Vladan P Cokic; Reginald D Smith; Bojana B Beleslin-Cokic; Joyce M Njoroge; Jeffery L Miller; Mark T Gladwin; Alan N Schechter
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

10.  Hydroxyurea treatment of sickle cell anemia in hospital-based practices.

Authors:  Robert P Ferguson; Anuradha Arun; Chris Carter; Stanley D Walker; Oswaldo Castro
Journal:  Am J Hematol       Date:  2002-08       Impact factor: 10.047

View more
  1 in total

1.  Hydroxyurea could be a good clinically relevant iron chelator.

Authors:  Khushnooma Italia; Roshan Colah; Kanjaksha Ghosh
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.